Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Rubio: 'Very short window', maybe days, for Hamas to accept deal
Al Mayadeen correspondent to southern Lebanon: Israeli warplanes launched a raid on the Ksar Zaatar neighborhood in western Nabatieh.
Al Mayadeen's correspondent in Gaza: The tower destroyed by the Israeli occupation in Gaza includes media offices, including Al Mayadeen's bureau.
Al Mayadeen's correspondent in Gaza: Four fetuses and three premature babies died at Nasser Medical Complex due to malnutrition
Lebanese Ministry of Health: One person was killed in an Israeli airstrike on a car in the town of Burj Qalawieh, south Lebanon.
Al Mayadeen correspondent: The first ship of the Maghreb fleet delivering aid to break the siege on Gaza departs from the port of Gammarth in Tunisia.
Channel 12: Airspace closed at Ramon Airport due to fears of drone infiltration
IOF Spokesperson: Sirens sounded over an aircraft infiltration in the Bir Ora area, and details are being examined
Drone infiltration sirens sound north of the Gulf of Aqaba
Al Mayadeen's correspondent in Gaza: The Israeli occupation carried out five extremely violent raids on the western areas of Gaza City

Alzheimer's drug approval optimistic amid promising results

  • By Al Mayadeen English
  • Source: Agencies
  • 17 Jul 2023 23:44
3 Min Read

Following clinical trial results, another Alzheimer's drug proven to slow cognitive decline is one step closer to US approval.

  • x
  • A sign for Eli Lilly & Co. outside their headquarters in Indianapolis on April 26, 2017. New research shows another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening. (AP)
    A sign for Eli Lilly & Co. outside their headquarters in Indianapolis on April 26, 2017. (AP)

As a consequence of clinical trial findings that were published in a reputable publication on Monday, a second Alzheimer's medication that has been shown to reduce cognitive loss moved one step closer to US approval.

After years of little advancement in the field, many experts have welcomed the results as significant advances. However, others have advised caution, characterizing the advantages as limited while highlighting the high prices and risks of life-threatening side effects.

A study published in the Journal of the American Medical Association (JAMA) found that the medicine donanemab reduced the progression of symptoms over an 18-month period by 35% in comparison to placebo in approximately 1,200 persons with early-stage Alzheimer's disease.

Read: 19-year-old Chinese man becomes youngest patient with Alzheimer's

Results from cognitive tests and participants' capacity to complete daily tasks were used to gauge this. Drugmaker Eli Lilly, which said it anticipates regulatory action in the United States by the end of the year, produces the medication, which is administered intravenously every four weeks.

The release of the new research coincides with the US Food and Drug Administration's decision to allow Leqembi, a medication created by Biogen and Eisai, to be covered by Medicare, the nation's sponsored insurance program for the elderly.

Both function by focusing on the protein amyloid beta, which damages cognition when it builds up in the brain.

Related News

UN report reveals cocaine in upward trend, meth market expands

288 people arrested by Europol in massive dark web crackdown

"These first-generation drugs are by no means perfect, but represent an important breakthrough," interim director of the UK Dementia Research Institute, Giles Hardingham, said in a statement.

However, he added that it was equally crucial to understand that Alzheimer's is a complex illness and that amyloid beta was merely one factor in its development.

However, Eric Widera of the University of California, San Francisco, and colleagues argued that it was too early to conclude that the new medications would be helpful in the long run. Such opinions appeared in an editorial that was published alongside the new results in JAMA.

They claimed that Donanemab and Leqembi, also known as lecanemab, do not treat Alzheimer's disease but rather cause "slightly less worsening" in patients.

"The modest benefits would likely not be questioned by patients, clinicians, or payers if amyloid antibodies were low risk, inexpensive, and simple to administer. However, they are none of these," the authors wrote.

Patients will still be responsible for thousands of dollars in out-of-pocket expenses even after Medicare covers 80% of the expenditures.

Additionally, three deaths that were most likely brought on by the therapies that cause brain bleeds occurred in the investigations of donanemab and Leqembi.

Given that anti-amyloid therapies also speed up brain atrophy, research indicates that it will be critical to gather more information as the treatments enter the real world to determine whether they continue to decrease cognitive decline past 18 months or if they have the opposite effect.

Additionally, since 96% of the patients in the donanemab trial were white despite the fact that Black and Latino persons had a much greater prevalence of Alzheimer's, this means that important demographics still remain understudied.

  • Eli Lilly
  • Alzheimer's Disease
  • Drug

Most Read

The damaged building in the Katara neighborhood, Doha, Qatar, September 9, 2025 (Social media)

Hamas delegation survives Israeli assassination attempt in Qatar

  • Politics
  • 9 Sep 2025
Pro-"Israel" conservative Charlie Kirk shot during Utah speech

American far-right activist Charlie Kirk shot dead during Utah speech

  • US & Canada
  • 11 Sep 2025
Uprising against Volker Turk at the Human Rights Council over Gaza.

Uprising against Volker Turk at the Human Rights Council over Gaza

  • Politics
  • 12 Sep 2025
A screengrab from the ad played on Fox News. (X Screengrab)

Fox airs ad warning Trump not to let Netanyahu 'play' him on Gaza

  • US & Canada
  • 11 Sep 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
President Nicolas Maduro gestures to supporters during the inauguration of a monument in China's honor on the 80th anniversary of the end of World War II, in Caracas, Venezuela, Wednesday, September 3, 2025 (AP)
Politics

Maduro warns of threats, urges 'battle for truth' to defend Venezuela

Damage is seen after an Israeli strike targeted a compound that hosted Hamas' political leadership in Doha, Qatar, Wednesday, Sept. 10, 2025. (AP Photo/Jon Gambrell)
Politics

Netanyahu informed Trump before deadly attack in Doha: Reports

Israeli Prime Minister Benjamin Netanyahu and US Secretary of State Marco Rubio hold a joint press conference at the Prime Minister's Office, during Rubio's visit, in occupied al-Quds, occupied Palestine, Monday, September 15, 2025 (AP)
Politics

Netanyahu warns of Israeli isolation, calls to boost self-reliance

Spain axes €700Mln arms deals with 'Israel' over Gaza genocide
Politics

Spain axes €700 mln arms deals with 'Israel' over Gaza genocide

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS